当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2015年
11期
111-112
,共2页
慢性阻塞性肺疾病%肺动脉高压%法舒地尔
慢性阻塞性肺疾病%肺動脈高壓%法舒地爾
만성조새성폐질병%폐동맥고압%법서지이
Chronic obstructive plumonary disease%Pulmonary hypertension%Fasudil
目的：评价不同给药次数的法舒地尔对慢性阻塞性肺疾病(COPD)继发肺动脉高压治疗效果的差异。方法将72例COPD继发肺动脉高压患者随机分为常规治疗组、每日1次组、每日2次组，其中常规治疗组26例，每日1次组25例，每日2次组21例。常规治疗组行吸氧、抗感染、化痰、平喘、强心利尿或无创呼吸机辅助通气等治疗；每日1次组和每日2次组分别在常规治疗基础上加法舒地尔30 mg每天1次和每天2次滴注治疗。比较各组患者治疗前后测定肺动脉收缩压、动脉血二氧化碳分压(PaCO2)、N末基末端脑钠肽前体(NT-proBNP)水平及住院时间差异。结果用药后3组患者肺动脉收缩压、PaCO 2、NT-proBNP均有不同程度改善，法舒地尔治疗组改善幅度高于常规治疗组(P<0.05)。两两比较中肺动脉收缩压、PaCO 2在常规治疗组与每日1次组、常规治疗组与每日2次组之间存在统计学差异(P<0.05)；NT-proBNP仅在常规治疗组与每日2次组之间存在统计学差异(P<0.05)。3组患者住院时间比较，差异无统计学意义。结论法舒地尔能降低COPD继发的肺动脉高压，改善肺通气及右心功能。增加法舒地尔给药次数未发现能进一步降低COPD患者的肺动脉收缩压。
目的：評價不同給藥次數的法舒地爾對慢性阻塞性肺疾病(COPD)繼髮肺動脈高壓治療效果的差異。方法將72例COPD繼髮肺動脈高壓患者隨機分為常規治療組、每日1次組、每日2次組，其中常規治療組26例，每日1次組25例，每日2次組21例。常規治療組行吸氧、抗感染、化痰、平喘、彊心利尿或無創呼吸機輔助通氣等治療；每日1次組和每日2次組分彆在常規治療基礎上加法舒地爾30 mg每天1次和每天2次滴註治療。比較各組患者治療前後測定肺動脈收縮壓、動脈血二氧化碳分壓(PaCO2)、N末基末耑腦鈉肽前體(NT-proBNP)水平及住院時間差異。結果用藥後3組患者肺動脈收縮壓、PaCO 2、NT-proBNP均有不同程度改善，法舒地爾治療組改善幅度高于常規治療組(P<0.05)。兩兩比較中肺動脈收縮壓、PaCO 2在常規治療組與每日1次組、常規治療組與每日2次組之間存在統計學差異(P<0.05)；NT-proBNP僅在常規治療組與每日2次組之間存在統計學差異(P<0.05)。3組患者住院時間比較，差異無統計學意義。結論法舒地爾能降低COPD繼髮的肺動脈高壓，改善肺通氣及右心功能。增加法舒地爾給藥次數未髮現能進一步降低COPD患者的肺動脈收縮壓。
목적：평개불동급약차수적법서지이대만성조새성폐질병(COPD)계발폐동맥고압치료효과적차이。방법장72례COPD계발폐동맥고압환자수궤분위상규치료조、매일1차조、매일2차조，기중상규치료조26례，매일1차조25례，매일2차조21례。상규치료조행흡양、항감염、화담、평천、강심이뇨혹무창호흡궤보조통기등치료；매일1차조화매일2차조분별재상규치료기출상가법서지이30 mg매천1차화매천2차적주치료。비교각조환자치료전후측정폐동맥수축압、동맥혈이양화탄분압(PaCO2)、N말기말단뇌납태전체(NT-proBNP)수평급주원시간차이。결과용약후3조환자폐동맥수축압、PaCO 2、NT-proBNP균유불동정도개선，법서지이치료조개선폭도고우상규치료조(P<0.05)。량량비교중폐동맥수축압、PaCO 2재상규치료조여매일1차조、상규치료조여매일2차조지간존재통계학차이(P<0.05)；NT-proBNP부재상규치료조여매일2차조지간존재통계학차이(P<0.05)。3조환자주원시간비교，차이무통계학의의。결론법서지이능강저COPD계발적폐동맥고압，개선폐통기급우심공능。증가법서지이급약차수미발현능진일보강저COPD환자적폐동맥수축압。
Objective To estimate therapeutic efficacy of difference doses of fasudil on pulmonary hypertension of chronic obstructive pulmonary disease (COPD) patients.Methods Seventy-two patients with COPD were treated with conventional group (26 cases), fasudil qd group (25 cases) and fasudil bid group (21 cases). The conventional group received routine treatment, including oxygen uptake, anti-infection, phlegm dissolving, relieving asthma, diuresis, noninvasive ventilation, etc. The fasudil qd group received 30mg fasudil one time daily in addition to the routine treatment; and the fasudil bid group received twice. We collected pulmonary artery systolic pressure, arterial partial pressure of carbon dioxide (PaCO2) and NT-proBNP (N-terminal pro-B-type natriuretic peptide)of these patients before and after treatment.Results After treatment, pulmonary artery systolic pressure, PaCO2 and NT-proBNP of all the patients were decreased significantly, which were more in fasudil groups than conventional group (P<0.05). There was no significant differences among the three groups in hospital stay.Conclusion Fasudil can reduce pulmonary hypertension secondary to COPD, improve pulmonary ventilation and function of right heart, but can not further reduce pulmonary hypertension of COPD patients when we enlarge fasudil doses.
